Why does NAD+ injection hurt?
The formulation is often acidic and hypertonic and the volume is large; several vendors now sell 'pH-adjusted' NAD+ for this reason. Whether that helps has not been studied.
Human trial data
NAD+ Side Effects
Small human studies of intravenous NAD+ and larger trials of oral precursors — no approval
Intravenous NAD+ has been given in small clinical studies; the consistent finding is that adverse effects are infusion-rate-dependent — chest tightness, nausea, cramping and flushing when given quickly, resolving when slowed. Subcutaneous NAD+ has essentially no published safety data. Oral precursors (NR, NMN) have been through placebo-controlled trials with benign profiles.
Research-use information only. Research-grade NAD+ is not an approved medicine; where trial or label figures appear below they belong to the pharmaceutical product studied, not to any research vial. This page does not give dosing or medical advice.
What is reported
Every rate carries its source. Where no source exists, no rate is printed.
| Effect | Rate (sourced) | Detail | Source |
|---|---|---|---|
| Infusion-rate effects (chest pressure, nausea, abdominal cramping, flushing) | not quantified | Reported with IV NAD+ when infused rapidly; abated with slower rates. | Grant et al. 2019 |
| Oral precursors (NR, NMN) | not quantified | Placebo-controlled trials up to 12 weeks report adverse events similar to placebo. | Martens et al. 2018 (NR); Yoshino et al. 2021 (NMN) |
What is not known
- •Subcutaneous NAD+ — no controlled data.
- •Long-term effects of raising NAD+ pharmacologically.
Mechanism-based cautions
- •Injection-site pain is commonly reported informally for subcutaneous NAD+; unquantified.
- •Theoretical concern that boosting NAD+ could support tumour metabolism; unresolved in the literature.
Regulatory status: Not approved as a drug; sold as a research chemical and, for oral precursors, as supplements.
References
- Grant R, et al. A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6 hour intravenous infusion of NAD+. Frontiers in Aging Neuroscience, 2019.
What is actually in a research vial
Everything above describes NAD+ the molecule. The risk specific to a research vial is different: it may not contain NAD+ at the labelled amount, and it may contain what the synthesis left behind. Identity (mass spectrometry), purity (HPLC), measured net content and an endotoxin result are the four lines on a certificate that bear on adverse effects, and only a certificate you can check at the laboratory tells you any of them. This is what we have verified for NAD+ so far.
Who sells NAD+, and what they document
35 of the 77 vendors on our scoreboard list NAD+ with a price we read on the product page (5 Sept 2026–2 Oct 2026). Of those, 31 name their testing laboratory, 24 publish certificates that resolve on the lab's own site, and 29 publish measured milligrams against the label. The full ranking, with every dated price, is on Best NAD+ Vendors.
| Vendor | Rubric | Lab named | Price read |
|---|---|---|---|
| MyPurePeptidepartner | 10/10 | Janoshik Analytical | $35.00 · 500mg · 30 Sept 2026 |
| Peptide Giantspartner | 10/10 | Janoshik Analytical · Vanguard Laboratory | $39.99 · 500mg · 2 Oct 2026 |
| Purgo Labspartner | 10/10 | SteriGenix · Freedom Diagnostics | $59.99 · 500mg · 2 Oct 2026 |
| Ameano Peptidespartner | 9/10 | Janoshik Analytical | $68.00 · 500mg · 2 Oct 2026 |
| Amino Clubpartner | 9/10 | ILS Labs | $69.99 · 500mg · 2 Oct 2026 |
Top 5 by rubric score; 30 more on the ranking page.
NAD+ certificates we have opened
None yet for NAD+ specifically. The COA library holds the certificates we have read for each vendor on other compounds, which is the next best signal of how that vendor documents a lot.